© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - At the Heart of Europe’s Cardiovascular Research Scene
Posted 6th February 2024

At the Heart of Europe’s Cardiovascular Research Scene

Founded in 2012, the European Cardiovascular Research Institute (ECRI) was established for the purposes of serving as a collaborative effort for European nations to undertake investigator-initiated cardiology studies.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

At the Heart of Europe’s Cardiovascular Research Scene
Technology to analyze medical data and predict risk

Founded in 2012, the European Cardiovascular Research Institute (ECRI) was established for the purposes of serving as a collaborative effort for European nations to undertake investigator-initiated cardiology studies. Cardiology Research Organisation of the Year 2023 – Europe awardee ECRI today facilitates both the design and execution of such studies and trials, with each proudly boasting full certification and adherence to ICH, GCP, and ISO standards and guidelines. At present, randomised trials are being carried out whereby ECRI is the sponsor, with these being possible thanks to scientific grants generously afforded by those in leading industry positions. Thanks to this groundbreaking initiative carried out with the support of industry leaders boasting expertise in their respective fields, a multicentre, multinational experience has been created that possesses endless opportunities for study and development in the realm of cardiovascular health.

As a non-profit institute that proudly brings together Europe’s top clinical researchers and supporting industry staff to carry out clinical studies aiming to demonstrably improve cardiovascular healthcare, the European Cardiovascular Research Institute nobly manages and implements such studies in line with international regulations and to a series of pre-established budgets and timelines. These efforts are rooted primarily in collaboration with experts from across Europe, which is where a considerable amount of its investigation sites are located, and trials carried out. The exception to the rule is the Global Leaders and Master Dapt studies, with these having sites across a multitude of continents in addition to Europe.

One clearly apparent strength of this united front is that it assembles a large network of both investigators and sites, serving to provide the ECRI with the unique advantage of being able to select a site quickly from one of its nearly 40 partner countries, with the large scale of this operation also offering a large pool of possible patients, enabling enrolments to be undertaken in a swift yet realistic manner. By involving pioneers in the field of cardiology from a host of countries, resources can be combined, and project managers sourced that are able to offer unique insight, something that is particularly effective when it comes to assessing the quality of the available clinical data and images.

Regarding the countries which presently enrol patients into ECRI studies, the list is expansive and spans multiple continents, highlighting how regions all over the world can come together effectively to work towards groundbreaking research on such a vital area of study. These countries are, Austria, Argentina, Australia, Bangladesh, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Denmark, Estonia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Kazakhstan, Kingdom of Bahrain, Luxembourg, Macedonia, Mexico, Netherlands, Poland, Portugal, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, UK, and Vietnam.

Across these 38 countries is almost a dozen representative experts who make up ECRI’s Scientific Advisory Board, with this esteemed group consisting of a series of like-minded scientists, cardiologists, and statisticians, each of whom has demonstrated a keen interest in pursuing the designing and execution of these clinical trials. In an effort to co-design and stimulate clinical investigations on a trans-Atlantic level, this board is inclusive of trialists from across Europe and faculty from other continents across the globe, and membership is pro bono and can be secured by invitation only.

Each and every project undertaken by the ECRI is also managed by a steering committee, with this distinguished group of individuals being comprised of true scientific and clinical leaders. An ECRI representative is too always on hand, ensuring that things run smoothly. Further solidifying the safety of all operations is a series of independent data and safety monitoring boards, as well as clinical events committees, with these groups present to guarantee patient safety, data integrity, and the assessment of outcomes are all upheld to the highest calibre.

Located at the very heart of ECRI is a desire to serve as a pioneer in the realm of trial leadership, with this being achieved through supporting industry, the sites, and subcontractors that in turn support it. Since it is a non-profit organisation, ECRI offers sponsorship capabilities inclusive of contracting and subcontracting, patient insurance, quality assurance, risk management, project oversight, and controlling budgets. This is incredibly important in today’s environment, as there is less funding available for clinical research, and the plethora of requirements that have to be fulfilled before a trial can be carried out have resulted in single companies finding it increasingly difficult to raise the necessary funds for their studies.

It is this environment that ultimately produced ECRI, with this institute being founded for the purposes of serving as an intermediary between academic leaders and the supporting industry vital in funding such endeavours. The successful relationships that have been forged are clear to see, and in the past decade or so, 12 studies have been carried out, with a particularly notable trial being named “Global Leaders” and consisting of 16,000 “all-comer” patients who were enrolled in 130 centres and hospitals across 18 countries in Europe, Australia, Brazil, Canada, and Singapore.

This study saw patients being treated with the drug bivalirudin (in the countries where it is available) and a biomatrix stent, which had been fully randomised to produce either ticagrelor and aspirin followed by one month of ticagrelor monotherapy for a course of 23 months, or an intensive dual antiplatelet therapy, with this course of treatment lasting for 24 months. The first patient in this trial was enrolled by Belgium’s Dr Aminian from the CHU in Charleroi, and the whole trial was operated under ECRI’s umbrella, and supported by grants from businesses such as Biosensors, AstraZeneca, and The Medicines Company.

Across this incredibly important trial, partner company Cardialysis was made responsible for carrying out project and data management, site monitoring, safety reporting, and carrying out ECG analysis, among other such tasks. Results from this trial were published in The Lancet in 2018, with the primary endpoint concluding that, “experimental treatment strategy [is] superior to reference treatment strategy on cumulative 2-year composite of all cause mortality and new Q-wave MI.” These results serve as just one example of the stellar work that has been carried out over the last decade, with exceptional results sure to continue well into the future with the host of cardiovascular clinical trials currently underway.

Quintessentially, the trials that have been carried out by the European Cardiovascular Research Institute have immeasurably benefited the lives of countless people across Europe and even further afield, and with more than 400 people dying from heart and circulatory diseases every day in the UK, these efforts are more important now than ever before, with these numbers only set to increase. As a result of the phenomenal work done by the European Cardiovascular Research Institute, it is our pleasure to provide it with this award, and we wish the team all the best in all of their future trials and studies.

For business enquiries, contact Ernest Spitzer from European Cardiovascular Research Institute on their website – https://www.ecri-trials.com/

Ernest Spitzer

Categories: Corporate Social Responsibility, News


You Might Also Like
Read Full PostRead - Eye Icon
Cryptocurrency Trends for 2022
Finance
19/01/2022Cryptocurrency Trends for 2022

While the crypto market has experienced an incredibly volatile year, it has also seen significant price hikes and sustained growth over the course of the previous 12 months.

Read Full PostRead - Eye Icon
Supporting the Assessment of Pandemic-Era Academics
Innovation
16/03/2022Supporting the Assessment of Pandemic-Era Academics

ExamSoft, a platform that has been lauded as the ‘Most Innovative Learning Assessment Platform’ in 2022 for the USA, has been making a difference in the academic industry by ensuring that remote examinations can be carried out in a reliable manner regardle

Read Full PostRead - Eye Icon
Pre-M&A Security Risks & Liabilities Assessment – 5 Tips & Best Practices
News
18/01/2024Pre-M&A Security Risks & Liabilities Assessment – 5 Tips & Best Practices

In the high-stakes world of mergers and acquisitions, cybersecurity risks and vulnerabilities have quietly emerged as a key consideration and a crucial cog that can make the whole deal fall flat. During the process of taking over a company, the acquirer assume

Read Full PostRead - Eye Icon
Accelerating New FinTech Products With Modular Front End Technology by Velmie
Innovation
20/01/2023Accelerating New FinTech Products With Modular Front End Technology by Velmie

Front end and UX always become a challenge and key success factor when building new tech products. In the FinTech space, it plays an even more important role considering high CAC costs and the average CLV metrics.

Read Full PostRead - Eye Icon
Mark Lyttleton, Prana Partners Founder: Presenting the Perfect Pitch
News
20/11/2023Mark Lyttleton, Prana Partners Founder: Presenting the Perfect Pitch

Mark Lyttleton, Prana Partners Founder: Presenting the Perfect Pitch Mark Lyttleton is the founder of Prana Partners, an organisation launched with the mission of increasing humanity and collaboration in business, sharing knowledge gained over decades of inves

Read Full PostRead - Eye Icon
CMA Clears BT/EE Merger
M&A
15/01/2016CMA Clears BT/EE Merger

The Competition and Markets Authority (CMA) has cleared BT’s anticipated acquisition of EE. This follows its provisional decision to clear the merger in October 2015.

Read Full PostRead - Eye Icon
Streamlining Your Online Payment Process: A New Era of Online Transactions
Finance
30/03/2023Streamlining Your Online Payment Process: A New Era of Online Transactions

When discussing streamlining, we mean ways to make your payment transactions more convenient. The number one benefit of streamlining is to make your customers happy, as they will be able to pay quickly and efficiently.

Read Full PostRead - Eye Icon
Why the Fintech Industry is Migrating to the Cloud
Finance
02/03/2023Why the Fintech Industry is Migrating to the Cloud

If you've been keeping up with the latest news in the fintech world, you might have noticed a common theme: more and more companies are moving their operations to the cloud. In fact, according to Mckinsey & Co, 54% of financial institutions expect to shift at

Read Full PostRead - Eye Icon
BGF announces further investment in SPEX Group Holdings Limited
Finance
24/01/2019BGF announces further investment in SPEX Group Holdings Limited

Aberdeen-headquartered SPEX Group Holdings Limited (“SPEX Group”) has secured a multi-million pound follow-on investment from its management team and BGF, the UK’s most active investor in growing businesses, to accelerate growth. BGF originally invested



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow